Respiratory syncytial virus

JPM26 Day 3: Sanofi CEO on RSV Scrutiny and Regeneron Dupixent Defense

21 hours ago talkbio0Tagged Beyfortus, Dupixent, JPM26, Paul Hudson, Regeneron, Respiratory syncytial virus, sanofi, United States Food and Drug Administration, Vaccines

JPM26; Sanofi; RSV; Beyfortus; Paul Hudson; FDA; vaccines; Dupixent; Regeneron

Just – Evotec Biologics Receives Gates Foundation Grant for AI-Driven Optimization of Monoclonal Antibody Developability

1 week ago talkbio0Tagged AI-driven, biotherapeutics, Country, developability, Drug Kinetics, Evotec SE, Financial cost, funding grant, Gates Foundation * *, Global Health, HIV, Immunogenicity (package insert), J.MD, low, Malaria, manufacturability, Manufactured Supplies, middle-income, Monoclonal Antibodies, Optimization, Platform, Respiratory syncytial virus, Stable status, Titer

Evotec SE; Gates Foundation; grant; J.MD; J.DESIGN platform; AI-driven optimization; monoclonal antibodies; biotherapeutics; developability; manufacturability; stability; immunogenicity; pharmacokinetics; titer; cost of goods; global health; affordable access; low- and middle-income countries; RSV; malaria; HIV

FDA reviews safety of approved RSV antibodies for infants

1 month ago talkbio0Tagged AstraZeneca, Beyfortus, Infant, Merck, nirsevimab, palivizumab, Respiratory syncytial virus, RSV antibodies, safety review, sanofi, United States Food and Drug Administration

FDA; RSV; nirsevimab; Beyfortus; palivizumab; RSV antibodies; infant safety review; Sanofi; AstraZeneca; Merck; respiratory syncytial virus

Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx PCR Platform to Support Submission to the U.S. FDA

2 months ago talkbio0Tagged Clinical Evaluations, Co-Diagnostics, Co-Dx PCR platform, COVID19 (disease), Flu A/B, multiplex test, point-of-care, regulatory submission, Respiratory syncytial virus, United States Food and Drug Administration

Co-Diagnostics; clinical evaluations; multiplex test; point-of-care; Co-Dx PCR Platform; FDA 510(k); Flu A/B; COVID-19; RSV; regulatory submission

Enanta Presses Ahead with RSV Drug Zelicapavir Despite Missing Primary Endpoint in Phase IIb Trial

4 months ago talkbio0Tagged Clinical Trials, Congestive heart failure, COPD, development aspects, Elderly (population group), Enanta, Hospitalization, Neoplasm Metastasis, Phase II B Trial, primary endpoint, rates, Respiratory syncytial virus, United States Food and Drug Administration, Zelicapavir

Enanta Pharmaceuticals; RSV; zelicapavir; Phase IIb trial; primary endpoint miss; secondary endpoints; clinical trials; FDA Fast Track; elderly; COPD; congestive heart failure; hospitalization rates; future development

Sanofi Tightens Grip on RSV with $1.15B Upfront Acquisition of Vicebio, Diversifying Beyond mRNA Vaccines

6 months ago talkbio0Tagged Acquisition, Homo sapiens, Metapneumovirus, Molecular Clamp Technology, non-mRNA vaccine, Respiratory syncytial virus, respiratory vaccines, RSV, sanofi, vaccine pipeline, Vaccines, Combined, Vicebio

Sanofi; Vicebio; acquisition; RSV; human metapneumovirus; combination vaccine; Molecular Clamp technology; non-mRNA vaccine; vaccine pipeline; respiratory vaccines